Verrica Pharmaceuticals (NASDAQ:VRCA) Posts Earnings Results, Beats Estimates By $1.27 EPS

Verrica Pharmaceuticals (NASDAQ:VRCA) released its quarterly earnings data on Friday. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $1.27, FiscalAI reports. The firm had revenue of $14.34 million for the quarter, compared to analyst estimates of $8.34 million.

Verrica Pharmaceuticals Stock Up 1.6%

VRCA traded up $0.06 during trading on Friday, reaching $3.93. 47,549 shares of the company’s stock were exchanged, compared to its average volume of 246,827. The business has a 50 day moving average price of $4.16 and a 200 day moving average price of $5.43. The company has a market capitalization of $37.14 million, a P/E ratio of -0.47 and a beta of 1.70. Verrica Pharmaceuticals has a fifty-two week low of $3.28 and a fifty-two week high of $13.60.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bridgeway Capital Management LLC bought a new stake in Verrica Pharmaceuticals during the 3rd quarter worth approximately $52,000. Qube Research & Technologies Ltd acquired a new position in Verrica Pharmaceuticals in the second quarter valued at about $28,000. AQR Capital Management LLC lifted its stake in Verrica Pharmaceuticals by 306.7% in the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock valued at $26,000 after buying an additional 44,275 shares in the last quarter. Invesco Ltd. increased its holdings in Verrica Pharmaceuticals by 64.8% during the 1st quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock worth $33,000 after purchasing an additional 29,256 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in Verrica Pharmaceuticals during the 2nd quarter worth approximately $66,000. 42.45% of the stock is owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.